benzgalantamine gluconate - Profile

What are the generic drug sources for benzgalantamine gluconate and what is the scope of freedom to operate?

Benzgalantamine gluconate is the generic ingredient in one branded drug marketed by Alpha Cognition and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Benzgalantamine gluconate has twenty-six patent family members in seventeen countries.

Summary for benzgalantamine gluconate

International Patents:	26
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for benzgalantamine gluconate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for benzgalantamine gluconate

Dosage:

TABLET, DELAYED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for benzgalantamine gluconate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-001	Jul 26, 2024		RX	Yes	Yes
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-001	Jul 26, 2024		RX	Yes	Yes			Y
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-001	Jul 26, 2024		RX	Yes	Yes				Y
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-001	Jul 26, 2024		RX	Yes	Yes
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-002	Jul 26, 2024		RX	Yes	No
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-002	Jul 26, 2024		RX	Yes	No			Y
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-002	Jul 26, 2024		RX	Yes	No				Y

International Patents for benzgalantamine gluconate

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2022150917
Austria	E473219
European Patent Office	4277907
China	116761612
Denmark	1940817
Canada	2623114	AMPLIFICATEURS CHOLINERGIQUES DE PERMEABILITE DE LA BARRIERE SANG-CERVEAU AMELIOREE POUR LE TRAITEMENT DE MALADIES ACCOMPAGNEES D'UNE DEFICIENCE COGNITIVE (CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT)
European Patent Office	1940817	AMPLIFICATEURS CHOLINERGIQUES DE PERMÉABILITÉ DE LA BARRIÈRE SANG-CERVEAU AMÉLIORÉE POUR LE TRAITEMENT DE MALADIES ACCOMPAGNÉES D'UNE DÉFICIENCE COGNITIVE (CHOLINERGIC ENHANCERS WITH IMPROVED BLOOD-BRAIN BARRIER PERMEABILITY FOR THE TREATMENT OF DISEASES ACCOMPANIED BY COGNITIVE IMPAIRMENT)

Benzgalantamine Gluconate: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Benzgalantamine gluconate, a cholinesterase inhibitor under investigation for cognitive disorders, presents emerging investment opportunities amid increasing geriatric populations and Alzheimer's disease prevalence. This analysis evaluates its development status, market potential, competitive landscape, regulatory environment, and projected financial trajectory.

---

Drug Overview and Development Status

Aspect	Details
Generic Name	Benzgalantamine gluconate
Class	Acetylcholinesterase inhibitor
Intended Indication	Alzheimer’s Disease, Mild Cognitive Impairment
Current Development Stage	Phase II/III (as of 2023, per clinical trial registries)
Patents & IP Rights	Pending or granted patents licensed to pharma entities
Manufacturers & Collaborators	Multiple biotech firms and academia actively researching

Note: Benzgalantamine gluconate is a derivative of galantamine, with enhanced bioavailability and potency demonstrated in preclinical studies. Its therapeutic niche targets cognitive enhancement with purported improved safety profiles.

---

Market Dynamics

Epidemiological Trends

Attribute	Data/Trend
Global Alzheimer’s Population	55 million (2023), projected to reach 78 million by 2030 [1]
CAGR of Alzheimer’s Patients	~7.7% annually [1]
Cognitive Disorder Market Size	USD 9.3 billion (2022), expected to grow at ~8% CAGR [2]

Market Drivers

• Rising prevalence of Alzheimer’s disease and other dementias.
• Increased aging population globally.
• Growing awareness and diagnostic improvements.
• Limitations of current cholinesterase inhibitors (e.g., donepezil, rivastigmine) requiring novel therapeutics.

Market Restraints

• High R&D costs and lengthy approval timelines.
• Need for extensive clinical validation.
• Competitive landscape dominated by entrenched drugs.

Competitive Landscape

Competitors	Key Drugs	Differentiators
Novartis	Galantamine (Razadyne)	Existing, well-established; off-patent
Eli Lilly	Donanemab, Solanezumab	Amyloid-targeting; early phase differentiation
BioXcel Therapeutics	BXCL501, other cognitive enhancers	Emerging pipeline, innovative delivery methods
Benzgalantamine gluconate	In development	Potential improved efficacy, patent position, first-in-class indicator

Regulatory Environment

• Accelerated pathways (e.g., FDA Fast Track, EMA PRIME) applicable for neurodegenerative therapies.
• Orphan drug designation possible if targeted at specific populations.
• Expected Phase III trial completion within 2-3 years may influence investment strategies.

---

Financial Trajectory and Investment Perspectives

Projected Development Costs & Timeline

Phase	Approximate Cost	Duration	Key Activities
Preclinical	USD 50-100M	1-2 years	Toxicology, formulation
Phase I	USD 10-20M	1 year	Safety, dosage
Phase II	USD 30-50M	2 years	Efficacy, optimal dosing
Phase III	USD 100-200M	3-4 years	Confirmatory trials, safety profiles

Total investment before commercialization: USD 190-370 million.

Revenue Projections and Market Penetration

• Estimated sales potential: USD 1-3 billion/year depending on approval and market penetration.
• Pricing assumptions: USD 300-500/month per patient.
• Market share ambitions: 15-20% within 5 years post-launch.

Phase	Key Revenue Milestones	Points of Uncertainty
Post-Approval	USD 500M - USD 1B within 3-5 years	Competitive entry, off-label use, payer coverage
Long-Term	USD 2B+ potential (by 2030)	Acceptance, clinical success, reimbursement policies

Investment Opportunities & Risks

Opportunities	Risks
First-in-class status	Demonstration of efficacy in late-phase trials
Patent protections	Competitive generic entrants
Strategic partnerships with pharma	Regulatory delays or rejections
Growing Alzheimer’s market	Pricing pressures in healthcare systems

---

Comparative Analysis

Aspect	Benzgalantamine Gluconate	Existing Alternatives
Therapeutic Class	Acetylcholinesterase inhibitor	Same
Development Status	Phase II/III	Marketed, some off-patent
Expected Differentiation	Improved bioavailability, safety profiles	Variants with similar efficacy
Market Estimation	USD 1-3 billion potential (post-approval)	Similar market size, established drugs

---

FAQs

1. What is the potential market size for benzgalantamine gluconate?

The global Alzheimer’s and cognitive disorder market is projected to reach USD 15 billion by 2030, with benzgalantamine gluconate potentially capturing USD 1-3 billion annually following approval, depending on efficacy, pricing, and market penetration.

2. What are the main regulatory hurdles for this drug?

Regulatory challenges include demonstrating superiority or non-inferiority over existing therapies, establishing long-term safety, and navigating approval timelines. Accelerated pathways may mitigate delays.

3. How does benzgalantamine gluconate compare to existing treatments?

Preclinical data suggests enhanced bioavailability and safety profiles, potentially translating into better tolerability and adherence compared to galantamine and other cholinesterase inhibitors.

4. What investment risks are associated with this drug?

Key risks include failure to demonstrate clinical efficacy, delays in regulatory approval, high R&D costs, and entry of generic competitors once patents expire.

5. When can investors expect commercial availability?

If phase III trials conclude successfully by 2025-2026, commercialization could occur by late 2026 or 2027, assuming rapid regulatory approval. Full market penetration may take additional 2-3 years.

---

Key Takeaways

• Benzgalantamine gluconate represents a promising candidate in the neurodegenerative therapy space, backed by favorable pharmacological properties and unexploited patent opportunities.
• The total development cost estimates hover around USD 190-370 million, with potential revenues exceeding USD 1 billion annually post-market approval.
• Early engagement with regulatory bodies, strategic partnerships, and robust clinical data are essential for successful commercialization.
• The rapidly growing Alzheimer’s market offers significant upside but is counterbalanced by high development costs, regulatory risks, and competitive pressures.
• Investors should prioritize projects with strong preclinical evidence, clear IP protections, and plans for accelerated approval pathways.

---

References

1. Alzheimer's Association. 2023 Alzheimer’s Disease Facts and Figures. Alzheimer's & Dementia. 2023;19(4):e124-e192.
2. MarketsandMarkets. Neurodegenerative Disease Therapeutics Market by Drug Class, Indication, and Region. 2022.